Skip to content

All Sections

Friday, March 6th 2026

Today's E-Edition

Business
Technology
Commercial Real Estate
Housing
Marketplace
The Mercury News
Branded Content
- Paid Content by Brandpoint
SUBSCRIBE NOW

Sign up for email newsletters

Subscribe

Account Settings Contact Us Log Out

Spoof a user

Sign up for email newsletters

Subscribe

Silicon Valley

Friday, March 6th 2026

Today's E-Edition

Business
Technology
Commercial Real Estate
Housing
Marketplace
The Mercury News

Create Watchlist

Nasdaq Composite

Silicon Valley 150

Markets:

News

Revive Therapeutics Ltd (OP:RVVTF)

0.0150 -0.0018 (-10.71%)

Streaming Delayed Price Updated: 10:08 AM EST, Mar 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Revive Therapeutics Ltd

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

News headline image

Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID

March 19, 2024

From Revive Therapeutics Ltd.

Via GlobeNewswire

News headline image

Revive Therapeutics Provides Corporate Update

March 12, 2024

From Revive Therapeutics Ltd.

Via GlobeNewswire

News headline image

Revive Therapeutics Explores the Use of Bucillamine for Long COVID

February 01, 2024

From Revive Therapeutics Ltd.

Via GlobeNewswire

News headline image

Revive Therapeutics Provides Update Evaluating Bucillamine for Nerve Agent Exposure with Defence Research and Development Canada

January 16, 2024

From Revive Therapeutics Ltd.

Via GlobeNewswire

News headline image

Revive Therapeutics Successfully Completes Development of a Novel Lyophilized Formulation of Bucillamine

January 10, 2024

From Revive Therapeutics Ltd.

Via GlobeNewswire

News headline image

Revive Therapeutics Announces Results of Annual General and Special Meeting of Shareholders

December 20, 2023

From Revive Therapeutics Ltd.

Via GlobeNewswire

News headline image

Revive Therapeutics Collaborates with Attwill Medical Solutions for the Clinical and Commercial Development of a Novel Lyophilized Formulation of Bucillamine

December 18, 2023

From Revive Therapeutics Ltd.

Via GlobeNewswire

News headline image

Revive Therapeutics Provides Update of Novel Bucillamine Formulation Development

November 21, 2023

From Revive Therapeutics Ltd.

Via GlobeNewswire

News headline image

Revive Therapeutics Enters into Worldwide Exclusive Agreement with Lawson Health Research Institute to Develop and Commercialize a Novel Long COVID Rapid Test

November 06, 2023

From Revive Therapeutics Ltd.

Via GlobeNewswire

News headline image

Revive Therapeutics Enters into Agreement with Defence Research and Development Canada for Evaluating Bucillamine for Nerve Agent Exposure

October 17, 2023

From Revive Therapeutics Ltd.

Via GlobeNewswire

News headline image

Revive Therapeutics Provides Update of Novel Bucillamine Formulation Development

October 11, 2023

From Revive Therapeutics Ltd.

Via GlobeNewswire

News headline image

Revive Therapeutics Announces Initiation of Novel Bucillamine Formulation Development

August 22, 2023

From Revive Therapeutics Ltd.

Via GlobeNewswire

News headline image

Revive Therapeutics Announces Filing of Patent for Bucillamine in the Treatment of Exposure to Chemical Warfare Agents

July 28, 2023

From Revive Therapeutics Ltd.

Via GlobeNewswire

News headline image

Revive Therapeutics Announces Results of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

July 06, 2023

From Revive Therapeutics Ltd.

Via GlobeNewswire

News headline image

Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

May 30, 2023

From Revive Therapeutics Ltd.

Via GlobeNewswire

News headline image

Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

May 12, 2023

From Revive Therapeutics Ltd.

Via GlobeNewswire

News headline image

Revive Therapeutics Announces Data Safety Monitoring Board Meeting Date on Phase 3 Clinical Study of Bucillamine in the Treatment of COVID-19

May 02, 2023

From Revive Therapeutics Ltd.

Via GlobeNewswire

News headline image

Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

April 18, 2023

From Revive Therapeutics Ltd.

Via GlobeNewswire

News headline image

Psyched: Canada's Case For Psilocybin Access And Microdose Trial, US Reform Update, Battle With DEA & More ↗

April 05, 2023

Canadian Patients Demand Access To Psilocybin: Federal Lawsuit, Official Petition & Failing Mechanism A patient-led lawsuit against the Canadian government is claiming access to therapeutic psilocybin...

News headline image

MDMA Transdermal Patch Moves Toward First-In-Human Trials: Latest Development Update ↗

April 03, 2023

Specialty drug delivery technology biopharma company Revive Therapeutics Ltd. (OTCQB: RVVTF) is undertaking research and development activities for its proprietary transdermal microneedle patch to...

News headline image

Revive Therapeutics Advances MDMA Transdermal Patch Development with Purchase of MDMA Supply from PharmAla Biotech

April 03, 2023

From Revive Therapeutics Ltd.

Via GlobeNewswire

News headline image

Meth Use Disorder Tackled With Psilocybin: Clinical Trial Begins Patient Enrollment ↗

March 28, 2023

Life sciences company Revive Therapeutics Ltd.

News headline image

Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder

March 28, 2023

First subject enrolled and initial top-line results expected in Q3-2023

From Revive Therapeutics Ltd.

Via GlobeNewswire

News headline image

Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

March 20, 2023

From Revive Therapeutics Ltd.

Via GlobeNewswire

News headline image

Revive Therapeutics Provides Update From Type C Meeting with FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

March 08, 2023

From Revive Therapeutics Ltd.

Via GlobeNewswire

News headline image

Psyched: 12 States Discuss Legalization Bills, Ceremonies For Veterans With TBI, Ketamine And MDMA Fast-Tracks & More ↗

February 13, 2023

Psychedelics Legislation: The Latest On Hawaii, Virginia, Missouri & More

News headline image

MDMA News: Optimi's New Drug Now Available, Revive Advances Transdermal Patch Evaluations ↗

February 06, 2023

Considering MDMA will likely be the first psychedelic to receive FDA approval for psychotherapeutic use to treat serious mental health conditions such as PTSD, seve

News headline image

Revive Therapeutics Secures MDMA Supply from PharmAla Biotech for MDMA Transdermal Patch Development

February 06, 2023

From Revive Therapeutics Ltd.

Via GlobeNewswire

News headline image

PharmaTher Holdings Nabs New Orphan Drug Status, Discusses Further Fast-Track, Partners For MDMA Patch ↗

February 03, 2023

Ketamine products manufacturer PharmaTher Holdings Ltd. (OTCQB: PHRRF) had lots happening this past week. Here are the company's top three news items.

News headline image

Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development of MDMA Transdermal Patch

February 03, 2023

From Revive Therapeutics Ltd.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

© 2025 FinancialContent. All rights reserved.

News Alerts
Member Services
Contact Us
Marketplace
- Real Estate
- Lottery
Classifieds
Subscribe Now

Terms of Use
Accessibility
Cookie Policy
Cookie Preferences
California Notice at Collection
Notice of Financial Incentive
Do Not Sell/Share My Personal Information
Arbitration
Powered by WordPress.com VIP

Copyright 2026 Silicon Valley. All rights reserved. The use of any content on this website for the purpose of training artificial intelligence systems, algorithms, machine learning models, text and data mining, or similar use is strictly prohibited without explicit written consent.